Mechanism of action of tasimelteon in non-24 sleep-wake syndrome: treatment for a circadian rhythm disorder in blind patients.

Abstract

ISSUE:

Many individuals with total blindness can develop a circadian rhythm disorder-called non-24 sleep wake syndrome-because they cannot detect light to resynchronize their sleep-wake cycles. A new melatonin 1 and melatonin 2 agonist tasimelteon improves sleep in these patients, resetting their circadian sleep-wake clocks.

• Authors: Stephen M Stahl
• Journal: CNS spectrums (CNS Spectr) Vol. 19 Issue 6 Pg. 475-8 (Dec 2014) ISSN: 1092-8529 [Print] United States
• PMID: 25422900 (Publication Type: Journal Article, Review)

Chemical References

• Benzofurans
• Cyclopropanes
• Receptors, Melatonin
• tasimelteon

Topics

• Benzofurans (therapeutic use)
• Blindness (complications)
• Cyclopropanes (therapeutic use)
• Humans
• Receptors, Melatonin (agonists)
• Sleep Disorders, Circadian Rhythm (drug therapy, etiology)